SunTrust Cuts Amedisys (AMED) to Neutral Following Updated Q2 Outlook
Tweet Send to a Friend
SunTrust Robinson Humphrey downgrades Amedisys (Nasdaq: AMED) from 'Buy' to 'Neutral'. PT $46.
Today's downgrade follows news late last ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Today's downgrade follows news late last ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
